Renata PLC, a listed drug manufacturer, has launched its first product in the Canadian pharmaceutical market, stated in a report.
The company will sell Desogestrel/Ethinylestradiol (0.15 mg/0.03 mg) tablets, an oral contraceptive. The medicine, manufactured at Renata’s Health Canada-approved facility, will be commercialised through a partnership with Ambicare Pharmaceuticals Inc under the brand names Miley 21 and Miley 28. This move marks a significant milestone for Renata as it enters the stringently regulated Canadian market.
Building on its expertise in navigating other regulatory markets, the company aims to expand its product portfolio in this new territory. This strategic partnership is expected to bolster its presence in the North American market.
For more updates, be with Markedium.
Leave a comment